SAN DIEGO, CA -- (MARKET WIRE) -- April 18, 2007 -- MultiCell Technologies, Inc. (OTCBB: MCET) has entered into an agreement with Merck KGaA & Co. Spittal/Drau Austria for the formulation and supply of one of the active components of MCT-125, MultiCell's Phase IIb drug for the treatment of chronic fatigue in patients with multiple sclerosis (MS).
